Mylan announces launch of Xulane

PITTSBURGH — Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals. The drug is used to prevent pregnancy in women who want to use a transdermal patch as a contraception method.



"Mylan is proud to continue expanding its portfolio of transdermal products through the launch of the first generic Ortho Evra Patch. Mylan's Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), which provides women with a high quality, affordable treatment option, once again demonstrates Mylan's commitment to bring to market difficult-to-develop and -manufacture medicines in support of our mission to expand access to high quality medicine," Heather Bresch, Mylan CEO, said.



Ortho Evra had sales in the United States of approximately $152.9 million for the 12 months ending Dec. 30, 2013, according to IMS Health.